Stock XLO XILIO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Xilio Therapeutics, Inc.

Equities

XLO

US98422T1007

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
1.01 USD -4.72% Intraday chart for Xilio Therapeutics, Inc. -21.09% +83.64%
Apr. 19 Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says MT
Apr. 01 Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Business Summary

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.

Number of employees: 73

Managers

Managers TitleAgeSince
René Russo CEO
 Chief Executive Officer 49 19-05-21
Kevin Brennan DFI
 Director of Finance/CFO 54 -
Katarina Luptakova CTO
 Chief Tech/Sci/R&D Officer - 22-09-30
Christopher Frankenfield COO
 Chief Operating Officer 42 21-02-28
Uli Bialucha CTO
 Chief Tech/Sci/R&D Officer - 21-03-31
Scott Coleman PRN
 Corporate Officer/Principal - 22-05-31
Stacey J. Davis PRN
 Corporate Officer/Principal - 22-05-16

Members of the board

Members of the board TitleAgeSince
Paul Clancy CHM
 Chairman 62 20-07-22
Daniel Curran BRD
 Director/Board Member 57 20-11-30
Tomas Jan Heyman BRD
 Director/Board Member 68 22-09-14
Sara Bonstein BRD
 Director/Board Member 43 21-08-16
Robert Ross BRD
 Director/Board Member 50 22-06-15
René Russo CEO
 Chief Executive Officer 49 19-05-21
Christina Rossi BRD
 Director/Board Member 48 21-03-31
Yuan Xu BRD
 Director/Board Member 56 22-01-03

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 34,479,103 23,477,593 ( 68.09 %) 5,617 ( 0.0163 %) 68.09 %

Shareholders

NameEquities%Valuation
GILEAD SCIENCES, INC.
26.67 %
7,345,473 26.67 % 8 M $
Rock Springs Capital Management LP
10.90 %
3,003,259 10.90 % 3 M $
Bain Capital Life Sciences LP
10.19 %
2,805,413 10.19 % 3 M $
Atlas Venture Life Science Advisors LLC
10.000 %
2,754,109 10.000 % 3 M $
Impresa Management LLC
6.926 %
1,907,671 6.926 % 2 M $
Octagon Capital Advisors LP
6.481 %
1,785,000 6.481 % 2 M $
SV Health Investors LLP
5.859 %
1,613,632 5.859 % 2 M $
MERCK & CO., INC.
5.386 %
1,483,414 5.386 % 2 M $
Takeda Ventures, Inc.
5.356 %
1,475,121 5.356 % 2 M $
RiverVest Venture Management LLC
5.234 %
1,441,444 5.234 % 2 M $

Company contact information

Xilio Therapeutics, Inc.

828 Winter Street Suite 300

02451, Waltham

+

http://www.xiliotx.com
address Xilio Therapeutics, Inc.(XLO)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.01 USD
Average target price
4.667 USD
Spread / Average Target
+362.05%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
XILIO THERAPEUTICS, INC. Stock Xilio Therapeutics, Inc.
+83.64% 36.54M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.12% 43.84B
MODERNA, INC. Stock Moderna, Inc.
+6.77% 41.68B
LONZA GROUP AG Stock Lonza Group AG
+45.26% 41.25B
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 27.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.01% 25.53B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.92% 18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.63% 12.29B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.16% 12.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.30% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. XLO Stock
  4. Company Xilio Therapeutics, Inc.